Thryv Therapeutics to Present at the 2025 Heart Rhythm Society Annual Meeting in San Diego, CA
Montreal, Quebec – April 15, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Heart Rhythm Society (HRS) Annual Meeting. The conference will be held at the San Diego Convention Center from April 24-27, 2025.
Preceding the conference on Wednesday, April 23rd, Dr. Amy Sehnert, Chief Medical Officer at Thryv Therapeutics, will speak at the Stanford Biodesign New Arrhythmia Technologies Retreat in San Diego. Her presentation, titled “Small Molecules for Arrhythmia Therapy,” will highlight emerging approaches to rhythm management.
The HRS Annual Meeting brings together leading scientists, clinicians, and industry professionals to discuss the latest advancements in heart rhythm disorders. The event serves as a key platform for unveiling cutting-edge research and fostering collaborations that drive innovation in patient care.
Thryv Therapeutics is honored to contribute to this important dialogue by presenting new clinical data from the Wave I, Part 2 study, which evaluates the effects of SGK-1 inhibition in patients with Long QT Syndrome Type 2 and Type 3.
Presentation Details
Title: SGK-1 Inhibition with LQT-1213 Significantly Reduces the QTcF in Patients with Congenital Long QT Syndrome in the Wave I, Part 2 Study
Presenter: Philip Sager, MD
Date: Sunday, April 27, 2025
Time: 8:24 – 8:34 a.m. PST
Location: Oral Abstract Hub 4 – Sails Pavillion, SDCC
To schedule a meeting with a Thryv representative at the HRS Annual Meeting, email admin@thryvtrx.com.
For more information about the HRS Annual Meeting, visit: https://heartrhythm.com/
More about the Wave I (Parts 1 and 2) can be found at: https://www.clinicaltrials.gov/study/NCT05906732.
About Thryv Therapeutics Inc.
Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK-1). For more information, please visit www.thryvtrx.com.
Media Inquiries
brittany@thryvtrx.com | 514 973 0915
